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The  use of near  infra  red spectroscopy  to  predict  the  concentration  of  two  pharmaceutical  co-crystals;
1:1  ibuprofen–nicotinamide  (IBU-NIC)  and 1:1 carbamazepine–nicotinamide  (CBZ-NIC)  has  been  eval-
uated.  A  partial  least  squares  (PLS)  regression  model  was  developed  for both  co-crystal  pairs  using  sets
of standard  samples  to create  calibration  and  validation  data  sets  with  which  to  build and  validate  the
models.  Parameters  such  as  the root  mean  square  error of  calibration  (RMSEC),  root  mean  square  error  of
prediction  (RMSEP)  and  correlation  coefﬁcient  were  used  to assess  the accuracy  and  linearity  of  the mod-
els. Accurate  PLS  regression  models  were  created  for both  co-crystal  pairs  which  can  be  used  to  predict
the  co-crystal  concentration  in  a powder  mixture  of  the  co-crystal  and  the  active  pharmaceutical  ingre-artial least squares
rediction
ctive pharmaceutical ingredient
rocess analytical tool
dient (API).  The  IBU-NIC  model  had  smaller  errors  than  the  CBZ-NIC  model,  possibly  due  to  the  complex
CBZ-NIC  spectra  which  could  reﬂect  the different  arrangement  of  hydrogen  bonding  associated  with  the
co-crystal  compared  to the  IBU-NIC  co-crystal.  These  results  suggest  that  NIR  spectroscopy  can  be  used
as a PAT  tool  during  a variety  of pharmaceutical  co-crystal  manufacturing  methods  and  the  presented
data  will  facilitate  future  ofﬂine  and  in-line  NIR  studies  involving  pharmaceutical  co-crystals.
© 2016  The  Authors.  Published  by Elsevier  B.V. This  is  an open  access  article  under  the  CC BY  license. Introduction
Pharmaceutical ingredients have conventionally been manu-
actured using batch processing with ofﬂine laboratory analysis
f samples to evaluate the quality and efﬁcacy of the process.
owever, in-line analytical measurements are now possible dur-
ng manufacturing, providing signiﬁcant scope for improving the
anufacturing process [1].
In-line monitoring of changes which occur during the manu-
acturing process can greatly increase process understanding and
dentiﬁcation of key parameters [2]. This concept of analysing at
he manufacturing stage can be carried out using process analyti-
al technology (PAT) and a quality by design (QbD) methodology.
he latest FDA guideline report for process analytical technology
tates ‘Quality cannot be tested into products; it should be built-in
r should be by design’ [1].
PAT tools form a vital part of the overall PAT framework. Put
imply, they are process analysers which are used for monitoring a
∗ Corresponding author.
E-mail address: clivewood@outlook.com (C. Wood).
ttp://dx.doi.org/10.1016/j.jpba.2016.06.010
731-7085/© 2016 The Authors. Published by Elsevier B.V. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
process. Combined with a QbD approach, the process can be opti-
mised with careful planning, design and using feedback from the
PAT tools. Parameters and variables can be adjusted accordingly to
suit the manufacturing needs and to achieve a speciﬁed outcome or
product. PAT tools have now become a necessary technology to use
when designing and improving the manufacture of pharmaceuti-
cal materials [3]. A large proportion of PAT tools are spectroscopic
techniques which often use the infra red, near infra red, X-ray,
Raman and ultra violet wavelengths [4]. Currently, numerous spec-
troscopic techniques combined with multivariate analysis, such as
partial least squares (PLS) and principal component analysis (PCA),
are being used for evaluation of the pharmaceutical properties of
powder, granules, tablets and so forth. An increasingly popular
spectroscopic technique is near infra red (NIR) spectroscopy. NIR is
extensively used in the pharmaceutical ﬁeld and is utilised in many
areas of production including raw material identiﬁcation, process-
ing control and ﬁnal product analysis. It is considered as a process
analyser, because of its ability to give multivariate qualitative [5],
quantitative [6], physical and chemical [7] information about a
material. In addition, NIR spectroscopy can generally penetrate
further into solid materials compared to mid-IR, and is therefore
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ommonly used to determine the purity of pharmaceutical mate-
ials such as excipients prior to the manufacturing processes [8].
Solid state characterisation techniques combined with multi-
ariate analysis and chemometrics have been used for pharmaceu-
ical co-crystal quantiﬁcation in recent years. Caliandro et al. [9] in
013, used both XRD and FT-IR combined with multivariate anal-
sis to quantify carbamazepine I, carbamazepine III, saccharin and
:1 carbamazepine-saccharin co-crystals. Similarly, in 2014 Soares
nd Carneiro [10] were able to evaluate the synthesis of 1:1 IBU-
IC co-crystals using Raman, powder X-ray diffraction (PXRD) and
ifferential scanning calorimetry (DSC) with partial least squares
egression and chemometric pre-treatments. Multivariate calibra-
ion is achieved by preparing a set of calibration samples with
nown analyte concentrations, measuring the spectral response
nd using the spectral data with a regression method, such as
rincipal component regression (PCR) or PLS, to model the ana-
yte concentration. The outcome is a regression vector which can
e optimised and the optimal model is used to predict the analyte
oncentration (or other properties) in unknown samples [11].
Pharmaceutical co-crystals have the potential to enhance the
hysicochemical properties of drug compounds [12]. Historically,
o-crystals have been referred to as molecular complexes [13,14].
here are now several published deﬁnitions to distinguish co-
rystals from polymorphs, salts, hydrates, solvates and amorphous
aterials. In 2005, Aakeröy and Salmon [15] proposed the following
eﬁnition for a co-crystal; “co-crystals are structurally homoge-
eous crystalline materials containing two or more components
resent in stoichiometric amounts, the components are discrete
eutral molecular reactants which are solids at ambient tempera-
ure”. Similarly, a pharmaceutical co-crystal is a co-crystal where
ne of the components is an active pharmaceutical ingredient (API)
ith suitable co-former(s) [12].
Reported methods for the preparation of co-crystals include
olution crystallisation or solution mediated phase transforma-
ion [16], solid-state grinding [17], liquid assisted grinding [18] or
olvent-drop grinding [19], hot melt extrusion [20] and ultrasound
ssisted cocrystallization [21]. For the analysis and characterisation
f pharmaceutical co-crystals, popular techniques include PXRD
nd DSC, usually combined with other techniques such as Raman,
IR, or IR spectroscopy.
Demonstrated by Kelly et al. [22] in 2012, NIR can be used
s an in-line PAT tool during the formation of 1:1 IBU-NIC co-
rystals using hot melt extrusion (HME). The team were able to
dentify key band shifts and band formations; particularly in the
egion 5200–4700 cm−1, when comparing the spectra of processed
amples to the 1:1 physical mixture of the starting components.
imilarly, Moradiya et al. [23] in 2014 used NIR for in-line charac-
erisation during HME of carbamazepine-cinnamic acid co-crystals
llowing determination of the position along the extruder bar-
el where co-crystal formation commenced by identifying NIR
and shifts. A case study, in 2014, using furosemide-adenine
o-crystals was used to demonstrate chemometric assisted NIR
pectral analysis with PCA which was able to pinpoint cocrys-
allization nucleation and solvent evaporation events during a
olvent evaporation method [24]. This case study then promoted
urther studies where Sarraguc¸ a et al. monitored cocrystalliza-
ion using NIR spectroscopy for furosemide-nicotinamide and
urosemide–p-aminobenzioc acid co-crystals during solvent evap-
ration [25,26]. Carbamazepine-saccharin co-crystals [27] and
ndomethacin-saccharin co-crystals [28] have also been monitored
uring antisolvent cocrystallization.
For the present study, two co-crystal pairs were chosen for
nvestigation using NIR spectroscopy; 1:1 ibuprofen-nicotinamide
nd 1:1 carbamazepine-nicotinamide. Ibuprofen is a nonsteroidal
nti-inﬂammatory drug (NSAID) and is the safest NSAID accord-
ng to the spontaneous adverse drug reaction reporting systemiomedical Analysis 129 (2016) 172–181 173
situated in the United Kingdom [29]. It suffers from high perme-
ability and low aqueous solubility and is classiﬁed as a class II
NSAID according to the biopharmaceutical classiﬁcation system
(BCS) [30]. Carbamazepine is an API normally associated with the
treatment of epilepsy and trigeminal neuralgia. It also suffers from
poor aqueous solubility and belongs to class II of the BCS [31]. Cru-
cially, both pairs can form a stable co-crystal when paired with
suitable co-formers. It has been shown that when ibuprofen and
carbamazepine form a co-crystal with the co-former nicotinamide,
their aqueous solubilities improve [32].
The aim of this study was  to utilise PLS regression to cre-
ate models which can predict the co-crystal concentration in a
powder mixture of the co-crystal and the API using NIR spec-
troscopy for two  co-crystals: 1:1 ibuprofen-nicotinamide and 1:1
carbamazepine-nicotinamide. The spectral information and regres-
sion results gathered by this study will assist the development of
cocrystallization techniques which do not involve any solvents or
additives during the process. Cocrystallization methods, such as
ultrasound assisted cocrystallization and hot melt extrusion are
increasingly being investigated because of their solvent-free capa-
bilities and ease of scale-up. This study is a step towards realising
the potential of these technologies for pharmaceutical cocrystal-
lization purposes by providing a co-crystal quantiﬁcation platform.
In addition, the data from this study will aid future in-line NIR moni-
toring of pharmaceutical co-crystals. If co-crystal quantiﬁcation can
be achieved throughout the manufacturing stage of pharmaceutical
co-crystals, the process can be optimised and co-crystal properties
tailored for speciﬁc needs.
2. Materials and methods
Ibuprofen, nicotinamide and carbamazepine were all purchased
from Sigma Aldrich. The ethanol solvent used for solution evapo-
ration was  of analytical grade.
2.1. IBU-NIC co-crystal molecular structure
The hydrogen bonding patterns are well documented for the
1:1 IBU-NIC co-crystal. The racemic ibuprofen binds to nicoti-
namide via an acid-pyridine motif, before a pair of dimers come
together through an amide-amide motif between the nicotinamide
molecules. Finally an amide-acid motif forms between the nicoti-
namide and the ibuprofen to create a ‘supramolecular macrocycle
structure’ [33] (Fig. 1).
2.2. CBZ-NIC co-crystal molecular structure
In this 1:1 co-crystal, a translation related hydrogen-bonding
pattern exists between the nicotinamide molecules and the car-
bamazepine molecules. The donors and acceptors of both amide
groups are fulﬁlled but the nitrogen atom within the ring struc-
ture of nicotinamide does not form any strong hydrogen bonds.
The crystal packing suggests hydrophobic interlocking rows with
. . . interactions between the carbamazepine and the nicoti-
namide rings [34] (Fig. 2).
2.3. Preparation of IBU-NIC co-crystals
The methods of preparation for both co-crystal pairs were
chosen according to their efﬁcacy and repeatability, several dif-
ferent techniques were trialled before the ﬁnal methods were
selected. Solvent mediated cocrystallization was carried out using
a microwave reactor (Monowave 300, Anton Paar GmbH, Austria).
1:1 equimolar weights of ibuprofen and nicotinamide, totalling
0.820 g, were mixed with 82 L of diluted water in a 30 mL  capac-
ity glass tube. The temperature was set to 80 ◦C and samples were
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Fig. 1. 1:1 IBU-NIC co-crystal molecular structure. Hydrogen bonding is shown by light bl
legend, the reader is referred to the web version of this article.)
Source: Fleischman et al. [34] 2003 via Cambridge Structural Database [35].
Fig. 2. 1:1 CBZ-NIC co-crystal molecular structure. Hydrogen bonding is shown by
light blue and red dashed lines. (For interpretation of the references to colour in this
ﬁgure legend, the reader is referred to the web  version of this article.)
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Nine different NIR regions were evaluated for each model. The
−1ource: Berry et al. [36] 2008 via Cambridge Structural Database [35].
ubjected to microwave irradiation with a holding time of 5 min
nd were then cooled to 40 ◦C and held for 1 min.
.4. Preparation of CBZ-NIC co-crystals
Solvent evaporation was carried out based on the method
eported by Shayanfar et al. [37] in 2014. 1:1 equimolar weights
f carbamazepine (2.363 g, 0.01 mol) and nicotinamide (1.221 g,
.01 mol) were dissolved in 20 mL  of absolute ethanol. The mix-
ure was gently heated and manually stirred with a glass rod for
0 min. Finally the mixture was left for 72 h at room temperature
o evaporate.
.5. Material analysis
PXRD was carried out using a Bruker D8 X-ray diffractometer.
cans from 2 to 30◦ (2theta) with a 0.01◦ step width and a 1s
ime count were carried out for all samples using CuK1 radia-
ion (1.5406 Ang wavelength). The receiving slit was 1◦ and the
cattering slit, 0.2◦. DSC was carried out using a Q2000 Differential
canning Calorimeter (TA Instruments, USA). The general heating
roﬁle used was a ramp from 40 to 200 ◦C with a heating rate of
0 ◦C/min.ue and red dashed lines. (For interpretation of the references to colour in this ﬁgure
2.6. Collection of NIR spectra
All NIR spectra were collected using an Antaris II NIR spectrome-
ter (Thermo Scientiﬁc, UK) in diffuse reﬂectance mode. Each sample
was placed in a standard glass vial which in turn was  placed upon
the integrating sphere diffuse reﬂection accessory. Each sample
reading averaged 32 individual spectra at a resolution of 8 cm−1
and were scanned over the region 4000–10000 cm−1 wavenum-
bers (2500–1000 nm wavelength) using Thermo Scientiﬁc RESULT
software. For each spectrum, 1557 data points were collected. The
software used a standard workﬂow to minimise interference from
the glass vial and collected a background before every individual
scan. To increase the signal to noise ratio, each sample was scanned
ﬁve times and a composite spectrum was created using TQ Analyst
software (Thermo Scientiﬁc, UK).
2.7. Samples
For the IBU-NIC co-crystal system, a PLS regression model was
designed using a set of standard samples consisting of a mixture of
1:1 IBU-NIC co-crystal and pure ibuprofen. The model for the CBZ-
NIC system was designed using a set of standard samples consisting
of a mixture of 1:1 CBZ-NIC co-crystal and pure carbamazepine.
The co-crystals used for the calibration and validation samples
were made using the methods described in Sections 2.3 and 2.4.
The validation samples were made from a separate batch of co-
crystal to the calibration samples for both co-crystals, they were not
used to create the PLS models, but they were used to validate the
models. The concentration of the calibration samples ranged from
pure ibuprofen/carbamazepine (0%) to 100% 1:1 co-crystal with
standards made at concentrations of 5% increments in between,
totalling 20 calibration samples. Validation samples were made at
the following concentrations: 2.5, 7.5, 12.5, 17.5, 27.5, 37.5, 52.5,
62.5, 72.5 and 92.5% 1:1 co-crystal, totalling 10 validation samples.
2.8. PLS regression conditions
The software used for PLS regression and chemometric pre-
treatments was TQ Analyst (Thermo Scientiﬁc, UK). PLS ﬁnds the
most relevant components based on those that maximise the
covariance between the data matrix and the response vector. Com-
bined with linear regression, PLS can predict the response of a
validation data set. PLS regression was performed using the aver-
aged IBU-NIC or CBZ-NIC calibration and validation samples. The
data was mean centred every time the PLS analysis was performed.whole region (10000–4000 cm wave numbers) was  selected,
then relatively large regions to avoid areas affected by noise were
chosen. Next, medium sized regions of interest were selected
C. Wood et al. / Journal of Pharmaceutical and Biomedical Analysis 129 (2016) 172–181 175
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ollowed by small sized regions which generally covered a small
umber of bands of interest.
The cross-validation was analysed for each model and the cross
alidation error did not signiﬁcantly improve when using more
han 2 factors in the majority of cases. Since the models were cre-
ted using 20 calibration samples, using more than 2 factors could
ave caused over-ﬁtting of the curves which could result in poor
rediction capabilities.
Five types of chemometric pre-treatments were used for both
o-crystal pairs which included the standard normal variate (SNV)
38], ﬁrst and second derivatives, Savitzky-Golay smoothing (SGS)
39] and Norris smoothing (NS) algorithms [40]. SNV pre-treatment
as used to compensate for differences in sample pathlength. The
NV was carried out over the full spectral range (10000–4000 cm−1
avenumbers) and effectively minimised any scaling or offset
ffects which may  have occurred.
First and second derivatives were used to improve the resolution
f overlapping bands, whilst also acting as a linear baseline correc-
ion method. It was beneﬁcial to view individual spectra in the 2nd
erivative to locate important bands which increase/decrease in
ntensity and may  shift to different wavenumbers when the co-
rystal concentration increased.
Smoothing techniques were applied to reduce noise. SGS was
arried out using 7 data points and a polynomial order of 3. NS was
Fig. 4. DSC thermograms for (A) IBU, (B) NIC, (C) 1:1 IBU-NIC PM,  (D) 1:11 IBU-NIC CC, (E) CBZ, (F) 1:1 CBZ-NIC PM and (G) 1:1 CBZ-NIC CC.
carried out using a segment length of 5 and a gap between segments
length of 5. Both smoothing techniques can affect the performance
of a PLS model.
3. Material characterisation
Pure 1:1 IBU-NIC and 1:1 CBZ-NIC co-crystals were used to cre-
ate the PLS regression models. PXRD and DSC techniques were used
to determine the purity of the synthesised co-crystals. Fig. 3 shows
the PXRD spectra for ibuprofen, nicotinamide, 1:1 IBU-NIC phys-
ical mixture (PM) and 1:1 IBU-NIC co-crystal (CC). Also displayed
are the PXRD spectra for carbamazepine, 1:1 CBZ-NIC PM and 1:1
CBZ-NIC CC.
The PXRD peak at ∼3.1◦ (2)  is a good indicator of 1:1 IBU-NIC
CC and is commonly compared with the ibuprofen peak situated at
∼6◦ (2)  to determine the purity of the co-crystal. If the co-crystal is
pure, then the peak at ∼6◦ (2)  will not be present in the spectrum.
In Fig. 3, it is clear that the ibuprofen peak is absent in the 1:1
IBU-NIC CC. The 1:1 CBZ-NIC CC has characteristic peaks located at
approximately 6.7◦, 9◦ and 10.15◦ (2).  The carbamazepine peak at
12.8◦ (2)  and the nicotinamide peak at 14.65◦ (2)  are indicators
for any remaining carbamazepine or nicotinamide in the co-crystal
sample. It is clear from the 1:1 CBZ-NIC CC spectrum that no residual
carbamazepine or nicotinamide were present.
 IBU-NIC CC, (E) CBZ, (F) 1:1 CBZ-NIC PM and (G) 1:1 CBZ-NIC CC.
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hole  region 10000–4000 cm−1.
DSC thermograms of ibuprofen, nicotinamide, 1:1 IBU-NIC PM
nd 1:1 IBU-NIC CC are shown in Fig. 4 along with carbamazepine,
:1 CBZ-NIC PM and 1:1 CBZ-NIC CC thermograms.
The melting points of ibuprofen and nicotinamide were found to
e 78.0 ◦C and 132.1 ◦C respectively. The eutectic point of 1:1 IBU-
IC PM was 72.8 ◦C and the melting endotherm situated at 91.0 ◦C
as attributed to the 1:1 IBU-NIC CC melting point. The pure 1:1
BU-NIC CC had a melting point of 91.1 ◦C. The DSC data conﬁrms
hat cocrystallization of ibuprofen and nicotinamide occurs during
he application of a standard temperature ramp.
For pure carbamazepine, there were two endothermic peaks
ocated at 175.9 ◦C and 192.3 ◦C which are associated with the
elting points of carbamazepine forms III and I respectively. The
xothermic peak at 177.5 ◦C indicates that the crystallisation of car-
amazepine form I occurs after form III has melted. The eutectic
oint of 1:1 CBZ-NIC PM was 126.0 ◦C and the melting point of 1:1
BZ-NIC CC was 162.4 ◦C.
NIR spectra were collected for ibuprofen, nicotinamide, 1:1 IBU-
IC PM,  1:1 IBU-NIC CC, carbamazepine, 1:1 CBZ-NIC PM and 1:1
BZ-NIC CC. The spectra are shown in Fig. 5.
The physical mixtures for both IBU-NIC and CBZ-NIC pairs dis-
lay a combination of the characteristic bands from the respective
ndividual components. 1:1 IBU NIC CC had unique bands at approx-
mately 4794, 5087, 6460, 6676, 8285 and 8393 cm−1, 1:1 CBZ-NIC
C also had unique bands at approximately 4636, 5002, 6495 and
696 cm−1, compared to the respective individual components and
heir physical mixtures.. IBU-NIC PLS model
The RMSEC, RMSEP and correlation coefﬁcient values were
ecorded for each region and various degrees of chemometric pre- 1:1 CBZ-NIC CC. For this ﬁgure, the spectra were pre-treated using SNV across the
treatments were used. Tables 1 and 2 display the RMSEC and RMSEP
values for each regression model respectively. The results suggest
that the level of chemometrics used had a signiﬁcant impact on
both error values. The most signiﬁcant reduction of the RMSEC and
RMSEP values was caused by applying the SNV. After using the SNV,
the evaluated regions then reacted differently to the various levels
of chemometrics. The ten models with the lowest RMSEC values
are highlighted in bold to help visualise their distribution related
to the different chemometrics that were applied.
Table 3 shows the ten PLS regression models which exhibited
the lowest RMSEC values. The correlation coefﬁcient values for the
models indicated that they were all well correlated linear models.
The difference between the RMSEC and RMSEP values were shown
to give an indication of the variance between the calibration and
validation data sets.
The wavenumber region of 7450–4700 cm−1 provided the
smallest calibration error of 0.77% when the 2nd Dev., SNV and
NS were applied. This region provided a model with relatively low
error values which could accurately predict the percentage yield of
1:1 IBU-NIC CC in samples where there is a mixture of ibuprofen
and the 1:1 IBU-NIC CC. This model (Model 1) exhibited a small
RMSEP value of 0.95% and the difference between the RMSEC and
RMSEP values was  only 0.18%. A small difference is a good indicator
of the accuracy and predictability of the model.
Model 1 is plotted in Fig. 6. Both the averaged calibration and
validation samples are shown to compare the measured co-crystal
yield to the PLS regression predicted co-crystal yield. This model
had a correlation coefﬁcient of 0.9997 and no outlying points were
observed.
The spectral and concentration factor loadings for both PLS
factors were calculated. The ﬁrst factor used 99.1% spectral infor-
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Table  1
IBU-NIC model: A matrix of RMSEC values of the PLS regression models when using different regions and different levels of chemometrics ( Bold = top ten models).
Region
(Wavenumber cm−1)
RMSEC Values (%)
Original SNV 1st Dev. SNV 1st Dev. SNV SGS 1st Dev. SNV NS 2nd Dev. SNV 2nd Dev. SNV SGS 2nd Dev. SNV NS
10000–5400 7.17 1.20 1.08 1.08 0.97 1.11 1.13 1.10
10000–4000 2.21 1.14 1.67 1.67 1.38 1.83 1.79 1.54
9000−8000  6.07 2.60 0.87 0.90 1.07 0.89 0.96 1.11
9000−4700  1.96 1.05 1.03 1.03 0.92 1.10 0.96 1.06
7450−7000  6.17 3.04 1.01 0.99 1.85 1.22 0.99 0.77
6820−6620 4.99 2.98 2.93 2.94 3.10 3.22 2.66 2.94
6100−5600  5.12 1.09 1.17 1.17 1.16 1.20 1.19 1.21
6080−6030 3.36 1.96 0.92 0.95 1.56  1.95 1.41 1.45
5100−4910 2.40 1.47 2.90 2.91 2.82 2.66 2.90 2.81
Table 2
IBU-NIC model: A matrix of RMSEP values of the PLS regression models when using different regions and different levels of chemometrics (Bold = top ten models).
Region
(Wavenumber cm−1)
RMSEP Values (%)
Original SNV 1st Dev. SNV 1st Dev. SNV SGS 1st Dev. SNV NS 2nd Dev. SNV 2nd Dev. SNV SGS 2nd Dev. SNV NS
10000−5400 11.80 0.91 1.52 1.52 1.37 1.88 1.73 1.64
10000−4000 4.61  1.74 3.13 3.12 2.29 3.57 3.38 2.69
9000−8000  12.50 1.84 1.54 1.59 1.48 1.60 1.80 1.93
9000−4700  3.57 1.10 1.78 1.78 1.42 1.93 1.74 1.70
7450−7000  9.82 4.34 1.28 1.26 1.77 1.57 1.52 0.95
6820−6620 4.64 2.99 2.18 2.17 2.50 4.72 2.69 2.47
6100−5600 4.58 1.96 1.67 1.68 1.44 1.88 1.80 1.56
6080−6030  3.03 1.52 0.92 0.94 1.20 1.69 1.62 1.48
5100−4910  2.86 1.60 3.23 3.23 3.33 2.86 2.92 3.00
Table 3
IBU-NIC model: The top ten PLS regression models in order of RMSEC value. The RMSEP and the difference between RMSEC and RMSEP are also shown along with the regions
and  chemometrics used.
Model Region (cm−1) Chemometrics RMSEC (%) RMSEP (%) RMSEC – RMSEP (%) Corr. Coef.
1 7450−7000 SNV, 2nd Dev., NS 0.77 0.95 −0.18 0.9997
2  9000−8000 SNV, 1st Dev. 0.87 1.54 −0.67 0.9996
3  9000−8000 SNV, 2nd Dev. 0.89 1.60 −0.71 0.9996
4  9000−8000 SNV, 1st Dev., SGS 0.90 1.59 −0.69 0.9996
5  9000−4700 SNV, 1st Dev., NS 0.92 1.42 −0.50 0.9995
6  6080−6030 SNV, 1st Dev. 0.92 0.92 +0.00 0.9995
7  6080−6030 SNV, 1st Dev., SGS 0.95 0.94 +0.01 0.9995
8  9000−8000 SNV, 2nd Dev., SGS 0.96 1.80 −0.84 0.9995
9  9000−4700 SNV, 2nd Dev., SGS 0.96 1.74 −0.78 0.9995
10  10000−5400 SNV, 1st Dev., NS 0.97 1.37 −0.40 0.9995
Table 4
CBZ-NIC model: A matrix of RMSEC values of the PLS regression models when using different regions and different levels of chemometrics (Bold = top ten models).
Region
(Wavenumber cm−1)
RMSEC Values (%)
Original SNV 1st Dev. SNV 1st Dev. SNV SGS 1st Dev. SNV NS 2nd Dev. SNV 2nd Dev. SNV SGS 2nd Dev. SNV NS
10000−9646 5.01 3.16 1.55 1.54 2.37 1.51 1.63 2.67
10000−5400 6.99 2.40 3.42 2.49 2.49 2.23 3.29 2.46
10000−4000  6.46 2.76 2.84 2.84 2.77 2.86 2.94 2.80
9000−8500 7.10 3.28 2.28 2.30 2.42 1.18 1.23 2.32
9000−5300 6.88 2.60 2.52 2.52 2.51 2.44 2.55 2.49
7200−5400  6.35 2.68 2.58 2.58 2.58 2.59 2.62 2.56
m
u
M
d
o
i
16881−6696 5.26 3.18 2.68 2.68 
6684−6457 5.58 2.52 2.58 2.58 
6075−5827 6.25 3.21 3.26 3.26 
ation and 99.7% concentration information. The second factor
sed 0.5% spectral and 0.2% concentration information.
The 2nd Dev. NIR spectral region, 7450–7000 cm−1, used for
odel 1 is shown in Fig. 7. This region exhibited clear and pre-
ictable differences between each spectrum. The majority of the
bserved bands in this range showed an increase in absorbance
ntensity as the 1:1 IBU-NIC CC concentration was decreased from
00% co-crystal to 0% (pure ibuprofen).2.66 2.70 2.68 2.57
2.58 2.56 2.59 2.60
3.33 2.82 2.95 3.31
It was difﬁcult to identify individual bands within the NIR spec-
tra because most are overtone or combination bands. The hydrogen
bonding involved in forming the IBU-NIC CC may  have caused some
of the observed band shifting. The most signiﬁcant shift in the
shown region was  from 7108 cm−1 to 7128 cm−1. Two  other shifts
were seen from 7070 cm−1 to 7081 cm−1 and from 7378 cm−1 to
7367 cm−1.
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Fig. 6. IBU-NIC model: PLS regression Model 1. Using the region 7450–7000 cm−1
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involved in forming the 1:1 CBZ-NIC CC may have caused some
F
1nd chemometrics 2nd Dev., SNV and Norris Smoothing.
. CBZ-NIC PLS model
The RMSEC, RMSEP and correlation coefﬁcient values were
ecorded for each region and various degrees of chemometric pre-
reatments were used. Tables 4 and 5 display the RMSEC and RMSEP
alues for each regression model respectively. The chemometric
re-treatments that were applied had a similar effect to the IBU-
IC model, with the SNV being important for reducing both error
alues. Again, the different evaluated regions reacted differently to
he various levels of chemometrics. The ten models with the lowest
MSEC values are highlighted in bold to help visualise their distri-
ution related to the different chemometrics that were applied.
Table 6 shows the ten PLS regression models which exhibited
he lowest RMSEC values. According to the correlation coefﬁcient
alues, the models were well correlated linear models.
The wavenumber region of 9000–8500 cm−1 provided the ﬁrst
nd second smallest calibration errors of 1.18% (Model 1) and 1.23%
Model 2). This region provided a model with relatively low error
alues which could accurately predict the percentage yield of 1:1
BZ-NIC CC in samples where there is a mixture of carbamazepine
nd the 1:1 CC.
ig. 7. IBU-NIC model: 2nd derivative NIR spectra over the region 7450–7000 cm−1 with N
:1  IBU-NIC CC.Fig. 8. CBZ-NIC model: PLS regression Model 2. Using the region 9000–8500 cm−1
and chemometrics 2nd Dev., SNV and SG Smoothing.
The best overall performing model was  determined as Model
2. Model 2 was chosen because it exhibited a small RMSEP value
of 3.53% compared to 4.26% for Model 1. The difference between
the RMSEC and RMSEP value was  only −2.30% for Model 2 where
as it was  signiﬁcantly larger for Model 1, −3.08%. Model 2 is plot-
ted in Fig. 8. Both the averaged calibration and validation samples
are shown to compare the measured co-crystal yield to the PLS
regression predicted co-crystal yield. This model had a correla-
tion coefﬁcient of 0.9992. An outlying point was observed for the
validation sample 52.5% CBZ-NIC CC yield.
The spectral and concentration factor loadings for both PLS
factors were calculated. The ﬁrst factor used 95.1% spectral infor-
mation and 99.4% concentration information. The second factor
used 0.6% spectral and 0.4% concentration information.
The 2nd Dev. NIR spectral region, 9000–8500 cm−1, used for
Model 2 is shown in Fig. 9. The majority of the observed bands in
this region exhibited an increase in absorbance intensity as the 1:1
CBZ-NIC CC concentration was decreased from 100% to 0% (pure
carbamazepine). It may  be possible that the hydrogen bondingof the observed band shifting. The band shifting for this system is
more subtle compared to the ibuprofen-nicotinamide system. The
most signiﬁcant observed shift is from 8690 cm−1 to 8705 cm−1.
orris smoothing of ibuprofen and the calibration samples with 25, 50, 75 and 100%
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Table  5
CBZ-NIC model: A matrix of RMSEP values of the PLS regression models when using different regions and different levels of chemometrics (Bold= top ten models).
Region
(Wavenumber cm−1)
RMSEP Values (%)
Original SNV 1st Dev. SNV 1st Dev. SNV SGS 1st Dev. SNV NS 2nd Dev. SNV 2nd Dev. SNV SGS 2nd Dev. SNV NS
10000−9646 3.29 3.59 3.92 4.00 3.04 5.49 4.73 3.71
10000−5400  5.03 2.71 4.22 3.09 3.11 3.07 4.52 3.00
10000−4000 5.59 3.51 4.20 4.21 3.91 4.58 4.51 4.09
9000−8500 4.26 4.28 3.32 3.32 3.30 4.26 3.53 3.33
9000−5300 4.97 3.00 3.13 3.13 3.15 3.04 3.08 3.03
7200−5400  4.87 3.12 3.18 3.18 3.20 3.09 3.13 3.10
6881−6696 4.44 3.95 3.41 3.41 3.36 3.41 3.33 3.11
6684−6457 4.08 2.99 3.00 3.00 2.98 3.15 3.07 2.99
6075−5827 5.05 4.23 4.12 4.12 4.34 3.42 3.69 4.34
Table 6
CBZ-NIC model: The top ten PLS regression models in order of RMSEC value. The RMSEP and the difference between RMSEC and RMSEP are also shown along with the regions
and  chemometrics used.
Model Region (cm−1) Chemometrics RMSEC (%) RMSEP (%) RMSEC – RMSEP (%) Corr. Coef.
1 9000−8500 SNV, 2nd Dev. 1.18 4.26 −3.08 0.9992
2  9000−8500 SNV, 2nd Dev., SGS 1.23 3.53 −2.30 0.9992
3  10000−9646 SNV, 2nd Dev. 1.51 5.49 −3.98 0.9988
4  10000−9646 SNV, 1st Dev., SGS 1.54 4.00 −2.46 0.9987
5  10000−9646 SNV, 1st Dev. 1.55 3.92 −2.37 0.9987
6  10000−9646 SNV, 2nd Dev., SGS 1.63 4.73 −3.10 0.9985
7  10000−5400 SNV, 2nd Dev. 2.23 3.07 −0.84 0.9973
8  9000−8500 SNV, 1st Dev. 2.28 3.32 −1.04 0.9972
9  9000−8500 SNV, 1st Dev., SGS 2.30 3.32 −1.02 0.9971
10  9000−8500 SNV, 2nd Dev., NS 2.32 3.33 −1.01 0.9971
Table 7
A comparison of the selected 1:1 IBU-NIC model (Model 1) and 1:1 CBZ-NIC model (Model 2), including the region, number of factors, chemometrics, RMSEC, RMSEP and
correlation coefﬁcient.
Co-crystal Pair Region (cm−1) PLS Factors Chemometrics RMSEC (%) RMSEP (%) Corr. Coef.
V, 2nd
V, 2nd
T
r
6
s
v
F
11:1 IBU-NIC 7450−7000 2 SN
1:1  CBZ-NIC 9000−8500 2 SN
he most prominent band associated with the co-crystal in this
egion was situated at 8751 cm−1.
. Model comparisonTo compare both co-crystal pairs, the selected model details are
hown in Table 7. The correlation coefﬁcient, RMSEC and RMSEP
alues were compared. Both co-crystal pairs achieved linear models
ig. 9. CBZ-NIC model: 2nd derivative NIR spectra over the region 9000–8500 cm−1 with
00%  1:1 CBZ-NIC co-crystal. Dev., NS 0.77 0.95 0.9997
 Dev., SGS 1.23 3.53 0.9992
with relatively low error values. In summary, the 1:1 IBU-NIC model
had lower RMSEC and RMSEP values than the 1:1 CBZ-NIC model.
For the 1:1 CBZ-NIC model, the validation sample data point
with a 52.5% measured co-crystal yield in Fig. 8 could be an out-
lier as it deviates from the linear model signiﬁcantly more than
any other data point. The squared residual for this point was  2.4
times larger than the sum of the squared residuals for the valida-
tion set when excluding the outlier. If this data point is removed
 SG smoothing of carbamazepine and the calibration samples with 25, 50, 75 and
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rom the validation set, the RMSEP value improves from 3.53% to
.02% when using all of the same conditions: SNV, 2nd Dev., SGS,
egion 9000–8500 cm−1. This would bring the 1:1 CBZ-NIC model
loser to the 1:1 IBU-NIC model when comparing prediction error.
Regarding the 2nd Dev. NIR spectra shown in Figs. 7 and 9, the
ajority of bands exhibited an increase in intensity as the co-crystal
oncentration decreased over the observed ranges. It is important
o note that over different spectral ranges not used for the chosen
odels, there were NIR bands with increased intensity due to an
ncrease in the co-crystal concentration. This could suggest the PLS
odels have reduced error values over a region where the intensity
f most NIR bands directly correlates to a decrease in the co-crystal
oncentration.
The 2nd Dev. 1:1 CBZ-NIC spectra used to create the models
ere relatively complex and exhibited more subtle differences
etween each co-crystal concentration, compared to the 1:1 IBU-
IC spectra. The complex 1:1 CBZ-NIC spectra could be caused by
he different arrangement of hydrogen bonding associated with
he co-crystal compared to the 1:1 IBU-NIC CC. This complexity
ould have impacted the PLS regression and may  have been the rea-
on why the error values were higher for the selected 1:1 CBZ-NIC
odel.
. Conclusion
The results demonstrate that NIR spectroscopy can be used to
ccurately distinguish between the individual components and the
o-crystal form of two different pharmaceutical co-crystal pairs.
lear differences in the NIR spectra were observed when shown in
he second derivative, and varying levels of chemometrics enabled
he PLS regression to achieve relatively low calibration and val-
dation error values. The ﬁndings suggest that NIR spectroscopy
ould be utilised as an accurate PAT tool for pharmaceutical co-
rystal manufacturing methods and could aid understanding of the
ocrystallization process.
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ppendix A.
MSEC =
√√√√
NC∑
i=1
(
YˆCi − Yi
)2
NC
(1)
q. (1) shows the relationship between the root mean square error
f calibration and the predictions of the calibration samples YˆCi
he measured concentration of the sample Yi and the number of
amples in the calibration set NC
MSEP =
√√√√
NP∑
i=1
(
YˆPi − Yi
)2
NV
(2)
q. (2) shows the relationship between the root mean square error
f prediction and the predictions of the validation samples YˆPi, the
easured concentration of the sample Yi and the number of sam-
les in the validation set NV .ppendix B. Supplementary data
Supplementary data associated with this article can be found, in
he online version, at http://dx.doi.org/10.1016/j.jpba.2016.06.010.iomedical Analysis 129 (2016) 172–181
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